CSIMarket
 
Chromadex Corporation  (CDXC)
Other Ticker:  
 
 
Price: $2.4000 $0.35 17.073%
Day's High: $2.4 Week Perf: 37.14 %
Day's Low: $ 2.02 30 Day Perf: 47.24 %
Volume (M): 588 52 Wk High: $ 2.40
Volume (M$): $ 1,410 52 Wk Avg: $1.51
Open: $2.07 52 Wk Low: $1.25



 Market Capitalization (Millions $) 169
 Shares Outstanding (Millions) 71
 Employees -
 Revenues (TTM) (Millions $) 84
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Chromadex Corporation
Chromadex Corporation is a science-based company that specializes in the research, development, and sale of ingredients used in various industries. They focus on creating products that promote health, wellness, and longevity. The company is known for its flagship ingredient, NIAGEN', which is a form of vitamin B3 that has been shown to have anti-aging properties. Chromadex also offers testing services to ensure the quality and safety of their ingredients.


   Company Address: 10900 Wilshire Blvd Los Angeles 90024 CA
   Company Phone Number: 388-6706   Stock Exchange / Ticker: NASDAQ CDXC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Chromadex Corporation

Legal Cannabis Company Surpasses Expectations in Fourth Quarter Earnings

CDXC, also known as ChromaDex Corporation, recently achieved a break-even point with a moderate increase in revenue. In the most recent fiscal period, their revenue rose by 0.953% to $21.20 million compared to the corresponding quarter a year prior. While this may seem positive, it is crucial to understand how CDXC performed in relation to its competitors in the legal cannabis industry. Unfortunately, CDXC underperformed in comparison to its contemporaries, who reported a business advance of 4.20% from the same quarter a year ago.
The previous quarter showed some improvement for CDXC, as their revenue increased by 8.725% from $19.50 million. Additionally, they achieved earnings of $0.114 million in the most recent fiscal period, a significant improvement compared to a net shortfall of $-1.418 million in the same quarter a year ago. Despite these positive aspects, CDXC's stockpiles have increased to $14.5 million, lower than the previous year's level of $14.7 million. Additionally, their accounts receivable has declined to $5.2 million, potentially indicating slowing demand.

Product Service News

ChromaDex Empowers US Military Special Operations Forces with Tru Niagen: A Groundbreaking Step towards Health and Performance Optimization

Published Wed, Dec 20 2023 2:04 PM UTC

In a groundbreaking move, ChromaDex Corp., the industry leader in nicotinamide adenine dinucleotide (NAD+) research and healthy aging, has unveiled its first-ever initiative to support the US Military. Their acclaimed NAD+ boosting supplement, Tru Niagen?, is now being utilized by the elite US Military Special Operations Forces, marking a momentous milestone in the productio...

Product Service News

Promising Results of High-Dose Niagen Supplementation in Parkinson's Disease Trial Spark Optimism in Patient Community

Published Thu, Nov 30 2023 1:34 PM UTC


A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging...

Product Service News

Revolutionary Clinical Study Reveals ChromaDex's Niagen Boosts NAD+ Levels Fourfold, Offering Hope for Ataxia Telangiectasia Patients

Published Wed, Nov 15 2023 1:32 PM UTC


A recently published phase II clinical study has revealed promising results for ChromaDex Corp. (NASDAQ: CDXC) and its patented Nicotinamide Riboside (NR) supplement, known as Niagen. The study, published in the journal Movement Disorders, highlights how Niagen supplementation can elevate Nicotinamide Adenine Dinucleotide (NAD+) levels up to fourfold, resulting in impro...

Chromadex Corporation

Chromadex Corporation Reports Strong Revenue in Q3 2023, Yet Remains Unprofitable, Raising Concerns

Chromadex Corporation, a global bioscience company focused on healthy aging, recently announced that it will be holding a conference call on November 8, 2023, to discuss its financial results for the third quarter of 2023. The company's financial results will be released in a press release after the close of regular stock market trading hours on the same day.
In the third quarter, Chromadex Corporation experienced positive revenue growth, with a 14.253% increase compared to the same reporting season the previous year. The company reported revenue of $19.50 million for the period ending on September 30, 2023. However, despite the revenue growth, Chromadex Corporation recorded a loss of $-0.01 per share.






 

Chromadex's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Chromadex does not provide revenue guidance.

Earnings Outlook
Chromadex Corporation does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com